Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Skye Bioscience, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies targeting the endocannabinoid system, with a primary emphasis on metabolic diseases such as obesity. The company operates within the biotechnology and pharmaceutical research industries and is publicly traded on the Nasdaq under the ticker SKYE. Its business model centers on advancing proprietary drug candidates through clinical development rather than commercial sales, and as such, the company does not generate product revenue.
Skye Bioscience’s strategic positioning is based on selectively targeting cannabinoid receptor pathways with the objective of achieving therapeutic benefits while avoiding historical safety concerns associated with earlier cannabinoid-based drugs. The company traces its origins to cannabis-related pharmaceutical research and underwent a strategic transformation and rebranding to Skye Bioscience in 2022, reflecting a sharpened focus on regulated, FDA-governed drug development in metabolic and inflammatory diseases.
Business Operations
Skye Bioscience operates as a single operating segment focused on pharmaceutical research and development, consistent with its status as a clinical-stage company. Its core activities include preclinical research, clinical trial execution, regulatory strategy, and intellectual property development. Revenue generation is currently limited to collaboration-related or incidental income, with operating expenses primarily driven by R&D and general administrative costs.
The company’s primary asset is its lead clinical program targeting the CB1 receptor pathway for obesity and related metabolic conditions. Skye controls its drug development assets internally and relies on third-party contract research organizations (CROs) and manufacturing partners for clinical trials and formulation work. Data inconclusive based on available public sources regarding any material revenue-generating partnerships or joint ventures.
Strategic Position & Investments
Skye Bioscience’s strategic direction is centered on advancing its lead metabolic disease candidate through clinical milestones while expanding its cannabinoid-based therapeutic pipeline. Growth initiatives focus on clinical validation, regulatory engagement with the FDA, and potential strategic collaborations that could accelerate development or commercialization. The company has publicly emphasized disciplined capital allocation and selective pipeline expansion rather than broad platform development.
Notable strategic actions include the acquisition and consolidation of cannabinoid-focused intellectual property to support its metabolic disease programs. Skye does not currently report a diversified portfolio of operating subsidiaries, and its investment activity is primarily directed toward internal R&D. Involvement in adjacent inflammatory or metabolic indications has been disclosed, though details beyond lead programs remain limited; data inconclusive based on available public sources.
Geographic Footprint
Skye Bioscience is headquartered in the United States, with primary operations conducted domestically. Its executive leadership, corporate governance, and regulatory activities are U.S.-based, aligning with its focus on FDA-regulated drug development and U.S. capital markets.
International presence is indirect and primarily related to clinical research activities, such as the use of global CROs or trial sites outside the U.S. The company does not report significant owned facilities or commercial operations in other regions, and its global footprint is best characterized as research-oriented rather than operationally expansive.
Leadership & Governance
Skye Bioscience is led by an executive team with experience in biotechnology, pharmaceuticals, and capital markets. The leadership philosophy emphasizes scientific rigor, regulatory compliance, and capital efficiency while advancing cannabinoid-based therapies into mainstream pharmaceutical development.
Key executives include:
- Punit Dhillon – Chief Executive Officer and President
- Andrew Leff – Chief Financial Officer (title and role verified; scope of responsibilities consistent with public disclosures)
- Thomas Hyde – Chief Scientific Officer (role associated with cannabinoid and metabolic research; data inconclusive on start date)
The board of directors provides oversight consistent with public company governance standards, including audit and compensation committees. Further details on individual directors and committee structures are disclosed in SEC filings; however, specific leadership succession plans or long-term governance initiatives are not comprehensively detailed in publicly available sources.